16 Tidholm A, Ljungvall I, Hoglund AB, Westling AB, Haggstrom J. Tissue Doppler and Strain Imaging in Dogs
with Myxomatous Mitral Valve Disease in Different Stages of Congestive Heart Failure.
Echocardiographic dimensions of 20 dogs
with myxomatous degeneration of the mitral valve were compared in this paper.
Not exact matches
In the QUEST Study, pimobendan significantly increased the survival time of dogs
with congestive heart failure (CHF) caused by
myxomatous mitral valve disease (MMVD).
Effect of pimobendan or benazepril hydrochloride on survival times in dogs
with congestive heart failure caused by naturally occurring
myxomatous mitral valve disease: the QUEST Study.
To determine whether chronic oral administration of pimobendan in dogs
with evidence of increased heart size secondary to preclinical
myxomatous mitral valve disease (MMVD) can delay the onset of clinical signs of congestive heart failure (CHF).1
In the VetSCOPE Study, pimobendan rapidly improved the quality of life in dogs
with CHF caused by
myxomatous mitral valve disease (MMVD).
Effect of Pimobendan in Dogs
with Preclinical
Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.
Effect of pimobendan in dogs
with preclinical
myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.
The EPIC Study showed a significant benefit in administering pimobendan in dogs
with preclinical
myxomatous mitral valve disease (MMVD)-- before the onset of congestive heart failure (CHF) cardiac - related death, or euthanasia (composite primary endpoint).
This groundbreaking study sought to answer a key question: Can pimobendan —
with proven efficacy in treating dogs
with congestive heart failure (CHF) caused by
myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?
The EPIC (Evaluation of Pimobendan In dogs
with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs
with stage B2
myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).
The aim of this study was to evaluate the efficacy of pimobendan
with conventional therapies on survival and reocurrence of pulmonary edema in dogs
with congestive heart failure (CHF) caused by
myxomatous mitral valve disease (MMVD).
The trial, titled «Effect of Pimobendan in Dogs
with Preclinical
Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted in veterinary cardiology.
The licence for Vetmedin (Boehringer Ingelheim) has been extended to cover dogs
with asymptomatic
myxomatous mitral valve disease (MMVD).
Effect of pimobendan or benazepril hydrochloride on survival times in dogs
with congestive heart failure caused by naturally occurring
myxomatous mitral valve disease: the QUEST study.